Tisdag 26 November | 05:41:28 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-03-28 09:00 Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-07-01 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2024-06-28 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-04-26 - Extra Bolagsstämma 2024
2024-03-29 - Bokslutskommuniké 2023
2023-11-24 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-22 - Årsstämma
2023-06-01 - Kvartalsrapport 2023-Q1
2023-05-16 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2023-03-31 - Bokslutskommuniké 2022
2023-01-20 - Extra Bolagsstämma 2022
2022-11-23 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-21 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2022-06-20 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-29 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2021-06-28 - Årsstämma
2021-05-25 - Kvartalsrapport 2021-Q1
2021-03-09 - Extra Bolagsstämma 2021
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Magnasense är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av olika läkemedelskandidater. Produktportföljen är bred och inkluderar huvudsakligen läkemedel för behandling av multipel skleros. Utöver huvudverksamheten erbjuds tillhörande kringtjänster. Verksamheten drivs i samarbete med övriga läkemedelsaktörer, där störst närvaro återfinns inom Norden.
2024-08-29 09:27:00

Lund, Sweden and Jerusalem, Israel, 29 August 2024 — Magnasense AB and Salignostics Ltd are pleased to announce the commencement of a feasibility study aimed at exploring potential technology development opportunities. This project will leverage Magnasense's innovative magnetic test strip technology in conjunction with Salignostics' advanced sample collection devices.

This collaborative project between Magnasense AB and Salignostics Ltd is a first step aiming to investigate combining their respective strengths with a focus on accuracy, efficiency, and user-friendliness of diagnostic tests.

Marco Witteveen, CEO of Magnasense AB, commented on the project:

"At Magnasense, we are always looking for ways to push the boundaries of diagnostic technology. This project with Salignostics allows us to explore new frontiers and expand the applications of our magnetic test strip technology. We are excited about the potential this feasibility study holds and look forward to the innovative solutions that may arise."

Dr. Guy Krief, deputy CEO at Salignostics LTD, added:

"This project with Magnasense aligns perfectly with our mission to revolutionize sample collection and diagnostic testing. Combining our expertise in sample collection with Magnasense's magnetic test strip technology opens up potential possibilities for technological advancements. We are eager to see the results of this feasibility study."

The feasibility study is set to commence in Q3 2024, with both companies dedicating resources and expertise to ensure full commitment and will be finalized in Q4 2024

For additional information, please contact:
Marco Witteveen, CEO, Magnasense AB
Email: ir@magnasense.com
The Company’s Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se

Salignostics Ltd
JBP Minrav building Floor 4
Hadassah Ein Kerem Medical Center
Jerusalem, Israel
office@salignostics.com

About Salignostics Ltd
Salignostics Ltd is at the forefront of sample collection technology, developing advanced devices that simplify and enhance the process of collecting biological samples. Their solutions are designed to support a wide range of diagnostic applications, contributing to better healthcare outcomes.